Safety and efficacy of intra-articular sodium hyaluronate (Hyalgan) in a randomized, double-blind study for osteoarthritis of the ankle.

Safety and efficacy of intra-articular sodium hyaluronate (Hyalgan) in a randomized, double-blind study for osteoarthritis of the ankle. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Safety and efficacy of intra-articular sodium hyaluronate (Hyalgan) in a randomized, double-blind study for osteoarthritis of the ankle. Abstract Text:

BACKGROUND: The potential benefit of hyaluronans in alleviating pain associated with osteoarthritis (OA) in joints other than the knee is of increasing interest. This double-blind, randomized, controlled study examined the safety and efficacy of intraarticular sodium hyaluronate (Hyalgan) in the treatment of pain associated with ankle OA. MATERIALS AND METHODS: Thirty consecutive patients with ankle OA documented by X-ray were randomized to treatment with five weekly injections of either sodium hyaluronate 2 mL (HYL) or phosphate-buffered saline 2 mL (control) in the tibiotalar joint. The primary endpoint was pain on movement and weightbearing using the Ankle Osteoarthritis Scale (AOS) 3 months after injection (a 100-mm visual analog scale [VAS]). Additional measures included the Western Ontario and McMaster Universities (WOMAC) OA Index and patient global assessment through 6 months; the Short Form-12 (SF-12) Health Survey at 3 months and 6 months; and all reported adverse events (AEs). RESULTS: The study groups differed only in age, baseline WOMAC pain, and AOS total scores; 80% of the HYL and 73% of the control patients completed the study. At Month 3, the primary endpoint of the study, the HYL group demonstrated a significantly greater improvement from baseline in AOS total score than did the control group (HYL: -17.4 +/- 5.0 mm; Control: -5.1 +/- 4.0 mm; p = 0.0407). The incidence of AEs was low, with no significant differences between the groups. There were no post-injection flares. CONCLUSION: Our study suggests that sodium hyaluronate may be a safe and effective option for pain associated with ankle OA, although larger studies are needed.

Safety and efficacy of intra-articular sodium hyaluronate (Hyalgan) in a randomized, double-blind study for osteoarthritis of the ankle. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Safety and efficacy of intra-articular sodium hyaluronate (Hyalgan) in a randomized, double-blind study for osteoarthritis of the ankle. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Foot & ankle international / American Orthopaedic

VOLUME: 29

Page Numbers: 657-63

Journal Abbreviation:

ISSN: 1071-1007

DAY: 12

MONTH: Jul

YEAR: 2008

Safety and efficacy of intra-articular sodium hyaluronate (Hyalgan) in a randomized, double-blind study for osteoarthritis of the ankle. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9433869

Safety and efficacy of intra-articular sodium hyaluronate (Hyalgan) in a randomized, double-blind study for osteoarthritis of the ankle. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Safety and efficacy of intra-articular sodium hyaluronate (Hyalgan) in a randomized, double-blind study for osteoarthritis of the ankle. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Safety and efficacy of intra-articular sodium hyaluronate (Hyalgan) in a randomized, double-blind study for osteoarthritis of the ankle.

AFFILIATION: Miami Veterans Affairs Medical Center, Surgical Service, 1201 NW 16th St, Miami, FL 33125, USA. michael.cohen@med.va.gov

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Foot Ankle Int

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Safety and efficacy of intra-articular sodium hyaluronate Hyalgan in a randomized, double-blind study for osteoarthritis of the ankle Related Publications

• Acute hemorrhagic nephritis.
• Alteration in goblet cell numbers and mucin gene expression in a mouse model of allergic conjunctivitis.
• Assay of mucins in human tear fluid.
• Brief report: intellectual and academic functioning in pediatric chronic kidney disease.
• C57BL/6 mice lacking Muc1 show no ocular surface phenotype.
• Clinical predictors of neurocognitive deficits in children with chronic kidney disease.
• Developmental expression of mucin genes ASGP (rMuc4) and rMuc5ac by the rat ocular surface epithelium.
• Differential regulation of membrane-associated mucins in the human ocular surface epithelium.
• Encephalitis.
• Functions of MUC16 in corneal epithelial cells.
• Mucin gene expression in human male urogenital tract epithelia.
• Mucin gene expression is not regulated by estrogen and/or progesterone in the ocular surface epithelia of mice.
• Pediatric case reports.
• Polycystic disease of the kidneys in a newborn infant.
• Quantitative analysis of mucins in mucosal secretions using indirect enzyme-linked immunosorbent assay.
• Release of membrane-associated mucins from ocular surface epithelia.
• Response to Protocol Review Scenario: A word from OLAW and USDA.
• Response to Protocol Review Scenario: A word from USDA.
• Safety and efficacy of intra-articular sodium hyaluronate (Hyalgan) in a randomized, double-blind study for osteoarthritis of the ankle.
• The ocular surface: the challenge to enable and protect vision: the Friedenwald lecture.
• The transition from childhood to adulthood with ESRD: educational and social challenges.
• Variation in the amount of T antigen and N-acetyllactosamine oligosaccharides in human cervical mucus secretions with the menstrual cycle.
• Vitamin A deficiency alters the expression of mucin genes by the rat ocular surface epithelium.